Core Viewpoint - Reckitt Benckiser Group has agreed to sell its Essential Home business to Advent International for $4.8 billion while retaining a 30% stake in the business [1] Group 1 - The transaction value for the sale of Essential Home is $4.8 billion [1] - Reckitt Benckiser will maintain a 30% ownership interest in the Essential Home business post-sale [1]

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc ("Reckitt Benckiser Group plc" or the "Company") (OTC PINK: RBGLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reckitt Benckiser Group plc investors who were adversely affected by alleged securities fraud between January 13, 2021 and July 28, 2024. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - Class actions have been initiated against Vestis Corporation, Reckitt Benckiser Group, and Tempus AI, highlighting significant legal challenges and potential financial implications for these companies [1][4][6]. Group 1: Vestis Corporation (NYSE: VSTS) - The class period for Vestis is from May 2, 2024, to May 6, 2025, with a lead plaintiff deadline of August 8, 2025 [2]. - The complaint alleges that Vestis made misleading statements about its business growth capabilities, particularly regarding customer retention and revenue generation [2]. - Following a disappointing financial report on May 7, 2025, Vestis' stock price plummeted from $8.71 to $5.44, a decline of approximately 37.54% in one day [3]. Group 2: Reckitt Benckiser Group plc (OTC: RBGLY) - The class period for Reckitt is from January 13, 2021, to July 28, 2024, with a lead plaintiff deadline of August 4, 2025 [4]. - Over 500 lawsuits have been filed against Reckitt, alleging failure to warn about the risks associated with its cow's milk-based formula, Enfamil, which is linked to a serious intestinal disease in premature infants [4][5]. - The allegations include misleading statements regarding the safety of Reckitt's products and the potential impact on sales and legal exposure [5]. Group 3: Tempus AI, Inc. (NASDAQ: TEM) - The class period for Tempus is from August 6, 2024, to May 27, 2025, with a lead plaintiff deadline of August 11, 2025 [6]. - The complaint claims that Tempus failed to disclose significant issues, including inflated contract values and questionable business practices that could jeopardize its financial stability [6]. - Following a critical report from Spruce Point Capital Management on May 28, 2025, Tempus' stock price fell from $65.87 to $53.20, a decrease of 19.23% [7][8].

Core Viewpoint - The Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC's American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025, for those who bought shares between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Class Action Details - Investors who purchased Reckitt ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 4, 2025 deadline [2][4]. - The lawsuit alleges that Reckitt failed to warn investors about the increased risk of necrotizing enterocolitis (NEC) in preterm infants due to its cow's milk-based formula, Enfamil, which misled investors regarding the company's business prospects [4]. Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [3]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [3].

Core Viewpoint - The Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC's American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025, for those who bought shares between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Class Action Details - Investors who purchased Reckitt ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The lawsuit alleges that Reckitt failed to warn investors about the increased risk of necrotizing enterocolitis (NEC) in preterm infants due to its cow's milk-based formula, Enfamil, which misled investors regarding the company's business prospects [4]. Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3].

NEW YORK, July 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc ("Reckitt Benckiser Group plc" or the "Company") (OTC PINK: RBGLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reckitt Benckiser Group plc investors who were adversely affected by alleged securities fraud between January 13, 2021 and July 28, 2024. Follow the link below to get more information and be contacted by a member of our team: ht ...

Core Viewpoint - Investors in Reckitt Benckiser Group PLC have until August 4, 2025, to file lead plaintiff applications in a securities class action lawsuit due to alleged failures in disclosing material information during the Class Period from January 13, 2021, to July 28, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Reckitt and certain executives failed to disclose material information, violating federal securities laws [3]. - Specific allegations include that preterm infants were at an increased risk of developing necrotizing enterocolitis (NEC) from consuming the company's cow's milk-based formula, Enfamil, which could impact sales and expose the company to legal claims [4]. - The lawsuit is titled Elevator Constructors Union Local No. 1 Annuity & 401(K) Fund v. Reckitt Benckiser Group PLC, et al., No. 25-cv-4708 [5]. Group 2: ClaimsFiler Information - ClaimsFiler is a free shareholder information service aimed at helping retail investors recover funds from securities class action settlements [6]. - The platform allows investors to register for free, access information on various securities class action cases, upload portfolio transactional data, and submit inquiries for free case evaluations [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit related to misleading statements and omissions concerning the safety of its Enfamil formula for preterm infants [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as January 13, 2021, to July 28, 2024 [3]. - Allegations include that Reckitt's cow's milk-based formula, Enfamil, posed an increased risk of necrotizing enterocolitis (NEC) in preterm infants, which was not disclosed [3]. - The lawsuit claims that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [3]. Group 2: Shareholder Actions and Deadlines - Shareholders are encouraged to register for the class action by August 4, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered losses due to deceit and illegal business practices [5]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [5]. - The firm seeks recovery for investors affected by misleading statements that led to artificial inflation of the company's stock [5].

Group 1 - A class action lawsuit has been filed against Reckitt Benckiser Group Plc for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Reckitt securities during the Class Period have until August 4, 2025, to request appointment as Lead Plaintiff [2] - Reckitt's American Depositary Share (ADS) price experienced significant declines following jury verdicts related to its subsidiary Mead Johnson's negligence in warning about health risks associated with its products [4][5] Group 2 - On March 15, 2024, an Illinois jury awarded $60 million against Reckitt's Mead Johnson subsidiary for failing to warn about the risk of necrotizing enterocolitis (NEC) in preterm infants, leading to a nearly 14% drop in Reckitt's ADS price [4] - A subsequent lawsuit against Abbott Laboratories resulted in a $495 million award, similarly impacting Reckitt's ADS price with a nearly 9% decline [5] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [6]

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt Benckiser Group plc made false statements regarding the safety of its cow's milk-based formula, Enfamil, particularly concerning the increased risk of necrotizing enterocolitis (NEC) in preterm infants [2]. - It is alleged that these misleading statements affected Reckitt's sales of Enfamil and exposed the company to legal claims, undermining the positive assertions made about its business and operations [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].